Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.

Journal of the National Cancer Institute - 7 Oct 2009

Siena Salvatore, Sartore-Bianchi Andrea, Di Nicolantonio Federica, Balfour Julia, Bardelli Alberto

Abstract excerpt

The monoclonal antibodies panitumumab and cetuximab that target the epidermal growth factor receptor (EGFR) have expanded the range of treatment options for metastatic colorectal cancer. Initial evaluation of these agents as monotherapy in patients with EGFR-expressing chemotherapy-refractory tumors yielded response rates of approximately 10%. The realization that detection of positive EGFR expression by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Cetuximab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Class I Phosphatidylinositol 3-Kinases

Share to Disease-Free Survival

Share to Panitumumab

Share to PTEN Phosphohydrolase

Share to Randomized Controlled Trials as Topic

Share to Research Design

Source

Open in PubMed Open full text

Identifiers

PMID: 19738166
DOI: 10.1093/jnci/djp280
PMCID: PMC2758310

Genes

EGFR
KRAS
BRAF
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.PMID 19738166Read ↗

Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations.Semantic proximity Read ↗

[Molecular predictive markers of EGFR-targeted therapy in metastatic colorectal cancer].Semantic proximity Read ↗

Predicting response to EGFR inhibitors in metastatic colorectal cancer: current practice and future directions.Semantic proximity Read ↗

Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer.Semantic proximity Read ↗

An empirical review on the resistance mechanisms of epidermal growth factor receptor inhibitors and predictive molecular biomarkers in colorectal cancer.Semantic proximity Read ↗

Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.Semantic proximity Read ↗

Biomarkers for predicting the efficacy of anti-epidermal growth factor receptor antibody in the treatment of colorectal cancer.Semantic proximity Read ↗

Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer.Semantic proximity Read ↗

Treatment of extended RAS/BRAF wild-type metastatic colorectal cancer with anti-EGFR antibody combinations.Semantic proximity Read ↗

EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy.Semantic proximity Read ↗

Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy.Semantic proximity Read ↗

Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.